Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Interleukin-23 in early disease development in rheumatoid arthritis.

Andersen T, Hvid M, Johansen C, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Deleuran B.

Scand J Rheumatol. 2015 Jun 19:1-5. [Epub ahead of print]

PMID:
26087654
2.

Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.

Greisen SR, Møller HJ, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Deleuran B.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4):498-502. Epub 2015 May 11.

PMID:
25962601
3.

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis.

Krintel SB, Dehlendorff C, Hetland ML, Hørslev-Petersen K, Andersen KK, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard HM, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Jørgensen A, Raun J, Ammitzbøll CG, Østergaard M, Stengaard-Pedersen K, Johansen JS.

Pharmacogenomics J. 2015 May 5. doi: 10.1038/tpj.2015.30. [Epub ahead of print]

PMID:
25939484
4.

Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial.

Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg BJ, Boesen M, Hetland ML, Christensen R, Møller J, Krogh NS, Stengaard-Pedersen K, Østergaard M.

Trials. 2015 Apr 21;16:178. doi: 10.1186/s13063-015-0693-2.

5.

Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with arthritis.

Cordtz R, Mellemkjær L, Glintborg B, Hetland ML, Dreyer L.

Ann Rheum Dis. 2015 Jul;74(7):1479-80. doi: 10.1136/annrheumdis-2014-206909. Epub 2015 Mar 5. No abstract available.

PMID:
25744102
6.

The efficacy of motivational counseling and SMS-reminders on daily sitting time in patients with rheumatoid arthritis: protocol for a randomized controlled trial.

Esbensen BA, Thomsen T, Hetland ML, Beyer N, Midtgaard J, Løppenthin K, Jennum P, Østergaard M, Sørensen J, Christensen R, Aadahl M.

Trials. 2015 Jan 27;16:23. doi: 10.1186/s13063-014-0540-x.

7.

The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.

Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J, Zink A, Gati T, Rojkovich B, Iannone F, Gremese E, van Riel PL, van de Laar MA, Lie E, Kvien TK, Canhão H, Fonseca JE, Rotar Ž, Loza E, Carmona L, Askling J, Johansson K, Finckh A, Dixon WG, Hyrich KL; EULAR Study Group for Registers and Observational Drug Studies.

Rheumatology (Oxford). 2015 Jun;54(6):1074-9. doi: 10.1093/rheumatology/keu446. Epub 2014 Nov 27.

PMID:
25433042
8.

Fetal growth and preterm birth in children exposed to maternal or paternal rheumatoid arthritis: a nationwide cohort study.

Rom AL, Wu CS, Olsen J, Kjaergaard H, Jawaheer D, Hetland ML, Vestergaard M, Mørch LS.

Arthritis Rheumatol. 2014 Dec;66(12):3265-73. doi: 10.1002/art.38874.

PMID:
25393524
9.

Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry.

Hetland ML, Jensen DV, Krogh NS.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-141-6. Epub 2014 Oct 30.

PMID:
25365104
10.

CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients.

Ammitzbøll CG, Steffensen R, Bøgsted M, Hørslev-Petersen K, Hetland ML, Junker P, Johansen JS, Pødenphant J, Østergaard M, Ellingsen T, Stengaard-Pedersen K.

Arthritis Res Ther. 2014 Oct 31;16(5):475. doi: 10.1186/s13075-014-0475-3.

11.

Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis.

Laustsen JK, Rasmussen TK, Stengaard-Pedersen K, Hørslev-Petersen K, Hetland ML, Østergaard M, Junker P, Hvid M, Deleuran B.

Arthritis Res Ther. 2014 Oct 30;16(5):474. doi: 10.1186/s13075-014-0474-4.

12.

The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program.

Grøn KL, Ornbjerg LM, Hetland ML, Aslam F, Khan NA, Jacobs JW, Henrohn D, Rasker JJ, Kauppi MJ, Lang HC, Mota LM, Aggarwal A, Yamanaka H, Badsha H, Gossec L, Cutolo M, Ferraccioli G, Gremese E, Bong Lee E, Inanc N, Direskeneli H, Taylor P, Huisman M, Alten R, Pohl C, Oyoo O, Stropuviene S, Drosos AA, Kerzberg E, Ancuta C, Mofti A, Bergman M, Detert J, Selim ZI, Abda EA, Rexhepi B, Sokka T.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):869-77. Epub 2014 Oct 20.

PMID:
25327997
13.

Reply to eLetter by Feldtkeller et al.

Sørensen J, Hetland ML.

Ann Rheum Dis. 2014 Dec;73(12):e78. doi: 10.1136/annrheumdis-2014-206612. Epub 2014 Oct 3. No abstract available.

PMID:
25281722
14.

Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.

Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML.

J Rheumatol. 2014 Dec;41(12):2352-60. doi: 10.3899/jrheum.131299. Epub 2014 Oct 1.

PMID:
25274894
15.

CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity'.

Greisen SR, Schelde KK, Rasmussen TK, Kragstrup TW, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Deleuran B, Hvid M.

Arthritis Res Ther. 2014 Sep 24;16(5):434. doi: 10.1186/s13075-014-0434-z.

16.

Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis.

Krol A, Garred P, Heegaard NH, Christensen AF, Hetland ML, Stengaard-Pedersen K, Junker P, Madsen HO, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Pedersen JK, Svendsen AJ, Tarp U, Pødenphant J, Lindegaard H, Østergaard M, Hørslev-Petersen K, Jacobsen S.

Scand J Rheumatol. 2015;44(1):8-12. doi: 10.3109/03009742.2014.918651. Epub 2014 Sep 10.

PMID:
25205362
17.

Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.

Højgaard P, Glintborg B, Hetland ML, Hansen TH, Lage-Hansen PR, Petersen MH, Holland-Fischer M, Nilsson C, Loft AG, Andersen BN, Adelsten T, Jensen J, Omerovic E, Christensen R, Tarp U, Ostgård R, Dreyer L.

Ann Rheum Dis. 2014 Jul 25. pii: annrheumdis-2014-205389. doi: 10.1136/annrheumdis-2014-205389. [Epub ahead of print]

PMID:
25063827
18.

Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome.

Sode J, Vogel U, Bank S, Andersen PS, Thomsen MK, Hetland ML, Locht H, Heegaard NH, Andersen V.

PLoS One. 2014 Jun 26;9(6):e100361. doi: 10.1371/journal.pone.0100361. eCollection 2014.

19.

Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.

Glintborg B, Gudbjornsson B, Krogh NS, Omerovic E, Manilo N, Holland-Fischer M, Lindegaard HM, Loft AG, Nordin H, Johnsen L, Oeftiger SF, Hansen A, Rasmussen C, Grondal G, Geirsson AJ, Hetland ML.

Rheumatology (Oxford). 2014 Nov;53(11):2100-9. doi: 10.1093/rheumatology/keu252. Epub 2014 Jun 17.

PMID:
24939677
20.

Decreases in diagnostic delay are supported by sensitivity analyses.

Sørensen J, Hetland ML.

Ann Rheum Dis. 2014 Jul;73(7):e45. doi: 10.1136/annrheumdis-2014-205590. Epub 2014 Apr 16. No abstract available.

PMID:
24739326
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk